Oncolytic Herpes Simplex Virus-Based Therapies for Cancer

Area of Science:

• Oncology
• Virology
• Immunotherapy

Background:

• Cancer presents a significant global health challenge, with increasing incidence of aggressive and treatment-resistant forms.
• Oncolytic virotherapy is an emerging strategy utilizing viruses to selectively infect and destroy cancer cells.
• Oncolytic herpes simplex virus (oHSV) is a genetically modified virus engineered for cancer treatment.

Purpose of the Study:

• To review the development and advancements in oncolytic herpes simplex virus (oHSV) therapy.
• To elucidate the antitumor mechanisms of oHSV.
• To summarize the clinical applications and outcomes of oHSV variants in treating various tumors.

Main Methods:

• Review of scientific literature on oHSV development and applications.
• Analysis of oHSV's mechanism of action, including direct oncolysis and immune stimulation.
• Compilation and discussion of data from clinical trials involving oHSV variants.

Main Results:

• oHSV can be engineered to specifically target and lyse cancer cells, sparing healthy tissues.
• The virus triggers an anti-tumor immune response, enhancing tumor recognition and destruction.
• Various oHSV variants have demonstrated potential in preclinical and clinical settings for diverse tumor types.

Conclusions:

• Oncolytic herpes simplex virus (oHSV) therapy represents a viable and evolving therapeutic option for cancer treatment.
• The dual mechanism of direct tumor cell killing and immune activation makes oHSV a promising immunotherapeutic agent.
• Ongoing clinical trials continue to explore the efficacy and safety of oHSV variants across a spectrum of cancers.